Health Condition 1: A15-A19- Tuberculosis
Conditions
Interventions
Intervention1: N-Acetylcysteine with standard antitubercular therapy: N-Acetylcysteine at a dose of 600 mg two oral tablets daily for one month upon clinicoradiological and or microbiological evidence
Sponsors
Department of Internal Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed TB. 2. Started on standard dose of anti-TB drugs regimen. 3. Patient with normal hepatic transaminases and bilirubin values at baseline. 4. Patient with clinical and radiological and/or microbiological evidence of tuberculosis
Exclusion criteria
Exclusion criteria: 1. Patient with age less than 18 years. 2. Previous TB infection or Multi Drug Resistant TB. 3.Not willing to consent for the study. 4. Hypersensitivity to N-Acetylcysteine. 5. Pregnant females. 6. Patients with Glasgow Comma Scale score less than 8. 7. Patients with deranged hepatic transaminases and or bilirubin at baseline. 8. Patient with peptic ulcer disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To calculate the difference in incidence of DILI in both treatment arms. Timepoint: 2 weeks,4 weeks and 8 weeks and if participant becomes symptomatic for ATT induced hepatitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Neha Sood
PGIMER Chandigarh
Outcome results
None listed